louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03060070: Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block
Official title: Comparison of the Analgesic Effect of Ketamine Versus Dexmedetomidine Added to Local Anesthetic in TAP Block for Lower Abdominal Cancer Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Postoperative Analgesia
Lower Abdominal Cancer
Lead sponsor: Assiut University
Sponsor class: OTHER
Collaborators: name: South Egypt Cancer Institute
First posted: 2017-02-23
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Comparing the analgesic effects of ketamine and dexmedetomidine when added to local anesthetic in TAP block for postoperative analgesia after lower abdominal cancer surgery.


Eligibility criteria: Inclusion Criteria:

* All patients ASA I and II to whom abdominal surgery for cancer will be conducted will be included in the study

Exclusion Criteria:

* Coagulopathies
* ASA III or IV, patient refusal, sensitivity to the used drugs

Primary outcomes:
measure: postoperative rescue morphine consumption
timeFrame: 24 hours postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: South Egypt Cancer Institute
state: Assiut University
Study officials:
References:
Clinical trial NCT03218670: Your Health in On Click
Official title: Your Health in On Click : Risk Behavior Among College Students
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: College Student Drinking
Eating Disorder
Stress, Psychological
Burn Out Syndrome
Cigarette Smoking
Hyperactivity
Health Behavior
Impulsive Behavior
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2017-07-14
Enrollment: 6000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: College students in France

Brief summary: A health education program was provided to higher education students aged between 18 and 25 years. Students were recruited either by posters and leaflets on campus, or during their mandatory medical survey at the University Medical Department. The objectives are to assess health behavior risk among college student : e.g eating disorders, binge drinking, electronic cigarettes and also stress, burnout


Eligibility criteria: Inclusion Criteria:

* Aged 18-25 years
* College students

Exclusion Criteria:

* No college students

Primary outcomes:
measure: Prevalence of binge drinking, eating disorders, burn out and other risk behaviors among college students
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Rouen
country: France
facility: Tavolacci
Study officials:
References:
Clinical trial NCT01277770: Studies of Kidney Transplant Outcome
Official title: Studies of Kidney Transplant Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Transplant Recipient (Kidney)
Steroid-Free Maintenance Immunosuppression
Post-Transplant Infections
Thymoglobulin
Keywords: Thymoglobulin
Kidney Transplant Recipients
Steroid-Free
Immunosuppression
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2011-01-17
Enrollment: 7500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Kidney transplant recipients at the University of Minnesota

Brief summary: The purpose of this study is to improve outcome for kidney transplant recipients. There has not been commensurate improvement in medium and long-term outcomes. Ongoing clinical research is necessary to improve transplant outcomes.

Detailed description: This study is looking at information already collected of transplant outcomes (short, medium and long-term complications and quality of life). This will specifically look at:

1. 10 year follow-up of steroid-free maintenance immunosuppression
2. A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients
3. An evaluation of the Delayed Graft Function (DGF) nomogram in Thymoglobulin treated recipients at the University of Minnesota

Eligibility criteria: Inclusion Criteria:

* Kidney Transplant Recipient at the University of Minnesota
* Kidney Transplant Recipients on steroid-free maintenance immunosuppression

Exclusion Criteria:

* Non-kidney transplant patients at the University of Minnesota

Primary outcomes:
measure: Data Analysis
timeFrame: 10 year followup
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University Of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Arthur Matas, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05111470: Analysis of the Kinematics of the Shoulder Complex in Sports "Overhead" Gestures Such as Kayaking Polo Throwing (Overhead)
Official title: Analysis of the Kinematics of the Shoulder Complex in Sports "Overhead" Gestures Such as Kayaking Polo Throwing (Overhead)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kayak Polo
Overhead
Lead sponsor: Ramsay Générale de Santé
Sponsor class: OTHER
Collaborators: name: European Clinical Trial Experts Network
First posted: 2021-11-08
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this study is to analyze the throwing gesture specific to the kayak polo. A throw in a seated position with fixation of the pelvis (by the seat) and antepulsion of the hip ipsilateral to the throwing shoulder.


Eligibility criteria: Inclusion Criteria:

* free and informed consent signed
* Benefiting from a social protection insurance
* Over 18 years-old
* Male
* Having a level of expertise greater than or equal to the national level 4

Exclusion Criteria:

* Present during the study or have presented within the year any musculoskeletal pathology in the right and left shoulder.
* Have a body mass index greater than 30kg / m2 (to ensure sufficient accuracy to measure the movements of the scapula)

Primary outcomes:
measure: Glenohumeral and scapulothoracic angles
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hopital privé Jean Mermoz
Study officials:
References:
Clinical trial NCT05116670: Comparison of Care Practices, Mortality and Morbidity of Very Preterm Infants Between Two Tertiary Centers in Northwest and South of China
Official title: Comparison of Care Practices, Mortality and Morbidity of Very Preterm Infants Between Two Tertiary Centers in Northwest and South of China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Morality
Morbidity;Newborn
Very Preterm Maturity of Infant
Keywords: care practices
mortality
morbidity
very preterm infant
comparison
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2021-11-11
Enrollment: 807
Sex: ALL
Minimum age (years): 1
Maximum age (years): 28
Standard ages: CHILD
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Very premature infants born with a gestational age between 22+0 - 31+6 weeks admitted to newborn centers of Qinghai Red Cross Hospital and Shenzhen Baoan Women's and Children's Hospital from Jan 1, 2018 to Dec 31, 2020.

Brief summary: Care practices, mortality and morbidity of very premature infants from two different tertiary centers were collected and compared, in order to discover areas for improvement where these two newborn centers can learn from each other.

Detailed description: This retrospective cohort study was conducted in two hospitals,Qinghai Red Cross Hospital and Jinan University affiliated Shenzhen Baoan Women's and Children's Hospital.Very premature infants born with a gestational age between 22+0 - 31+6 weeks admitted to both centers during 3 years from January 1, 2018 to December 31, 2020 were studied. In both centers, data including maternal characteristics, neonatal characteristics, obstetric practices, delivery room practices, and neonatal outcomes, were collected by data abstractors in each NICU. Anonymous data was transferred to Shenzhen and analyses were performed at the newborn center of SZH.

Eligibility criteria: Inclusion Criteria:

* Very premature infants born with a gestational age between 22+0 - 31+6 weeks；
* Admitted to both centers during 3 years from January 1, 2018 to December 31, 2020.

Exclusion Criteria:

* Infants not born at QHH or SZH (out born);
* Infants who had major congenital anomalies;
* Infants admitted after 7 days of life.

Primary outcomes:
measure: mortality
timeFrame: Jan 1,2018 - Dec 31,2020
measure: Major morbidity
timeFrame: Jan 1,2018 - Dec 31,2020
Secondary outcomes:
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Shenzhen Baoan Women's and Children's Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT04705870: Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis
Official title: Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Multiple Sclerosis
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2021-01-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with MS and who should undergo an MRI examination with or without injections of contrast agent as part of their care.

Brief summary: Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which four additional 20-minute sequences will be added.

MRI of routine care in the context of MS includes at least the following sequences:

* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
* SWI EPI 0.6 iso (7 minutes)

The sequences added by the search are:

* SWI non EPI QSM 6 echo (10 minutes)
* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)
* SWI EPI to TR equivalent to SWI non EPI (6 minutes)

These sequences will be acquired before or after the injection of gadolinium (if present in the examination of routine care). For examinations carried out with injection, the order of carrying out the 4 post-injection SWI sequences will be random.


Eligibility criteria: Inclusion Criteria:

* Patients over 18
* With MS defined according to the McDonald's revised clinical or radiological spatial and temporal dissemination criteria, with onset of symptoms \<5 years
* To benefit as part of care from an MRI with or without injection of gadolinium
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

* Patient benefiting from a legal protection measure
* Pregnant or breastfeeding woman

Primary outcomes:
measure: percentage of lesions showing the central vein sign with the SWI EPI sequence that also show the central vein sign with the candidate sequence
timeFrame: 1 day
measure: percentage of lesions which do not present the sign of the central vein with the SWI EPI sequence but which present it with the candidate sequence
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hhopital fondation adolphe de rothschild
Study officials:
References:
Clinical trial NCT01141270: Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application
Official title: Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application. A Randomised, Open Label, Cross Over Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: recombinant human follicle stimulating hormone
pharmacokinetics
bioequivalence
Lead sponsor: Polymun Scientific GmbH
Sponsor class: INDUSTRY
First posted: 2010-06-10
Enrollment: 32
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Comparative pharmacokinetics study after single subcutaneous application of AFOLIA and the reference product (Gonal-f®).

Objective: To demonstrate equivalence within the 80%-125% margin of the reference product for the area under the curve (AUC) of AFOLIA compared to (Gonal-f®).


Eligibility criteria: Inclusion Criteria:

* Healthy female volunteers
* Age between 18-38 years
* Body mass index 17-29 kg/m2
* Woman of child bearing potential must agree to practice effective barrier methods for birth control
* Use of oral contraceptives for at least 3 months before study entry
* Regular menstruation cycle (25-34 days) before initiation of oral contraception
* Presence of both ovaries
* Normal findings in medical history and physical and gynaecological examination unless the investigator considers an abnormality to be clinically irrelevant for this study
* Signed informed consent

Exclusion Criteria:

* Polycystic ovary syndrome (PCOS)
* History of hypersensitivity to FSH (Ovary Hyperstimulation Syndrome, OHSS)
* Impaired thyroid function (treated or untreated)
* History of malignant disease
* AST and/or ALAT \> 2 x ULN
* Other clinically relevant findings (ECG, blood pressure, physical, gynecological examination, laboratory examination)
* Smoking habits of more than 5 cigarettes per day
* Abuse of alcoholic beverages and drugs
* Participation in a clinical trial within 3 weeks prior to the study
* Foreseen inability to attend to scheduled study visits
* Symptoms of a clinically relevant illness during 3 weeks prior the first study day
* Pregnancy or lactation period
* Any medical condition that, in the opinion of the investigator, would interfere with safety of the subject or interference of the objectives of the study

Primary outcomes:
measure: Area under the serum concentration curve (AUC) of FSH
timeFrame: 0 -192h after FSH injection
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical University Vienna
name: Michael Wolzt, aoUniv.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06840470: Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
Official title: Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Sebaceous Hyperplasia
Keywords: Lesions on both sides of the face
Topical imiquimod
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2025-02-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Each subject's face will be divided randomly into an imiquimod-treated side and an untreated control side.
Primary purpose: TREATMENT

Brief summary: This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.


Eligibility criteria: Inclusion Criteria:

* Patient has sebaceous hyperplasia lesions on both sides of the face. At least one sebaceous hyperplasia lesion on each side of the face is 1 mm or more in size.
* If of child-bearing potential, subject agrees to the use of highly effective contraception during study participation. For women of childbearing potential, acceptable pregnancy prevention measures will include abstinence, barrier methods, chemical methods, or surgical.
* Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

* Current use or prior use of a retinoid (e.g. tretinoin) within the last 4 weeks.
* Prior use of imiquimod on the treated area.
* Concurrent use of 5-fluorouracil, aminolevulinic acid (photodynamic therapy), or psoralen therapy, or use of any of these within the last 4 weeks.
* Concurrent facial peels or cosmetic laser therapy on the treated areas.
* Nursing, pregnant or planning to become pregnant.
* Immunocompromised status (e.g. organ transplantation recipients or patients on cyclosporine).
* Current participation in other investigational trials.
* Known or suspected history of a clinically significant systemic disease (e.g., immunological deficiencies), unstable medical disorders (e.g., unstable diabetes), life-threatening disease or current malignancies.
* Known hypersensitivity to any of the following (in any dosage form): imiquimod or any component of the study medications.
* Received radiation therapy and/or anti-neoplastic agents within 3 months prior to study entry.

Primary outcomes:
measure: Complete and 75% clearance rates (clearance refers to reduction in total lesional area) at 16 weeks of treated lesions
timeFrame: 16 weeks
Secondary outcomes:
measure: Mean change in Sebaceous Hyperplasia (SH) count
timeFrame: 16 weeks
measure: Mean change in Sebaceous Hyperplasia (SH) diameter
timeFrame: 16 weeks
measure: Adverse events (AE) associated with imiquimod 5% cream when used in the treatment of sebaceous hyperplasia
timeFrame: Up to 8 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Sunny Wong, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01865370: Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hyperlipidemia
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2013-05-30
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Kochujang pills on improvement of blood lipids. The investigators measured improvement of blood lipids parameters , including Total Cholesterol, LDL-C, Triglyceride and HDL-C, and monitored their blood pressure.


Eligibility criteria: Inclusion Criteria:

* Males and females 19-55 years old
* Total Cholesterol 200\~260 mg/dl or LDL-C 110\~190 mg/dl
* Able to give informed consent

Exclusion Criteria:

* Allergic or hypersensitive to any of the ingredients in the test products
* History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
* History of alcohol or substance abuse
* Participation in any other clinical trials within past 2 months
* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
* Pregnant or lactating women etc.

Primary outcomes:
measure: Changes in Total Cholesterol
timeFrame: 12 weeks
measure: Changes in LDL-C (LDL Low Density Lipoprotein-cholesterol)
timeFrame: 12 weeks
Secondary outcomes:
measure: Changes in Triglyceride
timeFrame: 12 weeks
measure: Changes in HDL-C(High Density Lipoprotein-cholesterol)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
state: Jeollabuk-do
Study officials:
References:
citation: Lim JH, Jung ES, Choi EK, Jeong DY, Jo SW, Jin JH, Lee JM, Park BH, Chae SW. Supplementation with Aspergillus oryzae-fermented kochujang lowers serum cholesterol in subjects with hyperlipidemia. Clin Nutr. 2015 Jun;34(3):383-7. doi: 10.1016/j.clnu.2014.05.013. Epub 2014 Jun 9.
Clinical trial NCT06031870: Pelvic Floor Rehabilitation Study (Beckenboden-Rehabilitationsstudie - BREST)
Official title: Beckenboden-Rehabilitationsstudie (BREST)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postpartum Urinary Incontinence
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2023-09-11
Enrollment: 52
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the effectiveness of standard care, pelvic floor muscle training or vaginal pessary for the treatment of postpartum urinary incontinence.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* gave birth within the 12 weeks prior to the postpartum visit
* postpartum urinary incontinence
* able to understand and give consent in German

Exclusion Criteria:

* treatment for postpartum urinary incontinence that started prior to inclusion
* any neurologic disease that impairs bladder function

Primary outcomes:
measure: patients' self-reported satisfaction with the treatment
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Alzey
country: Germany
facility: Die GynPraxis
city: Bad Kreuznach
country: Germany
facility: Die GynPraxis
city: Lampertheim
country: Germany
facility: Die GynPraxis
city: Mainz
country: Germany
facility: Die GynPraxis
Study officials:
References: